RT Journal Article
SR Electronic
T1 Decreased SARS-CoV-2 viral load following vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.06.21251283
DO 10.1101/2021.02.06.21251283
A1 Matan Levine-Tiefenbrun
A1 Idan Yelin
A1 Rachel Katz
A1 Esma Herzel
A1 Ziv Golan
A1 Licita Schreiber
A1 Tamar Wolf
A1 Varda Nadler
A1 Amir Ben-Tov
A1 Jacob Kuint
A1 Sivan Gazit
A1 Tal Patalon
A1 Gabriel Chodick
A1 Roy Kishony
YR 2021
UL http://medrxiv.org/content/early/2021/02/08/2021.02.06.21251283.abstract
AB Beyond their substantial protection of individual vaccinees, it is hoped that the COVID-19 vaccines would reduce viral load in breakthrough infections thereby further suppress onward transmission. Here, analyzing positive SARS-CoV-2 test results following inoculation with the BNT162b2 mRNA vaccine, we find that the viral load is reduced 4-fold for infections occurring 12-28 days after the first dose of vaccine. These reduced viral loads hint to lower infectiousness, further contributing to vaccine impact on virus spread.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the ISRAEL SCIENCE FOUNDATION (grant No. 3633/19) within the KillCorona-Curbing Coronavirus Research Program. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethics committee of Maccabi Healthcare Services, Tel-Aviv, Israel. IRB number: 0066-20-MHS.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTo protect patient privacy, data is only available through a remote server, pending MTA.